Formulation of Neulasta® (pegfilgrastim)

Advanced Drug Delivery Reviews

Volumn 60, Issue 1, 2008, Pages 50-58

  Piedmonte, Deirdre Murphy ^a   Treuheit, Michael J ^a  

^a AMGEN INC   (United States)

Author keywords

(pegfilgrastim); Formulation; Neulasta ; PEGylation; r metHuG CSF

Indexed keywords

DEGRADATION; PROTEINS; SURFACE ACTIVE AGENTS; THAWING;

BUFFER TYPE; PROTEIN CONCENTRATION; SORBITOL; SURFACTANT CONCENTRATION; TONICITY MODIFIERS;

DRUG DELIVERY;

ACETIC ACID; CITRATE SODIUM; FORMIC ACID; GLUTAMIC ACID; GLYCEROL; MANNITOL; POLYSORBATE 20; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SODIUM CHLORIDE; SORBITOL; SUCCINIC ACID; SUCROSE; ANTINEOPLASTIC AGENT;

ANALYTIC METHOD; DRUG DEGRADATION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; FREEZE THAWING; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; ANIMAL; CHEMISTRY; HUMAN; METHODOLOGY; PHARMACEUTICS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; FILGRASTIM; HUMANS; HYDROGEN-ION CONCENTRATION; TECHNOLOGY, PHARMACEUTICAL;

EID: 36549084078     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.04.017     Document Type: Review

References (55)

1. Nicola N. Colony Stimulating Factors vol. 49 (1990), Marcel Dekker, Inc., New York
2. Hill C.P., Osslund T.D., and Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 5167-5171
3. Ricci M.S., and Brems D.N. Common structural stability properties of 4-helical bundle cytokines: possible physiological and pharmaceutical consequences. Curr. Pharm. Des. 10 (2004) 3901-3911
4. Herman A.C., Boone T.C., and Lu H.S. Characterization, Formulation, and Stability of Neupogen [Filgrastim), a Recombinant Human Granulocyte-colony Stimulating Factor vol. 9 (1996), Plenum Press, New York
5. Arakawa T., Prestrelski S.J., Narhi L.O., Boone T.C., and Kenney W.C. Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J. Protein Chem. 12 (1993) 525-531
6. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 10 (2004) 1235-1244
7. Frampton J.E., Lee C.R., and Faulds D. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48 (1994) 731-760
8. Abuchowski A., van Es T., Palczuk N.C., and Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252 (1977) 3578-3581
9. Hamidi M., Azadi A., and Rafiei P. Pharmacokinetic consequences of PEGylation. Drug Deliv. 13 (2006) 399-409
10. B Greenwald R. PEG drugs: an overview. J. Control Release 74 (2001) 159-171
11. Delgado C., Francis G.E., and Fisher D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carr. Syst. 9 (1992) 249-304
12. Harris J., and Chess R.B. Effect of PEGylation on pharmaceuticals. Nat. Rev., Drug Discov. 2 (2003) 214-221
13. Roberts M.J., Bentley M.D., and Harris J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54 (2002) 459-476
14. Inada Y., Furukawa M., Sasaki H., Kodera Y., Hiroto M., Nishimura H., and Matsushima A. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 13 (1995) 86-91
15. Yamaoka T., Tabata Y., and Ikada Y. Distribution and tissue uptake of poly[ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83 (1994) 601-606
16. Kinstler O.B., Brems D.N., Lauren S.L., Paige A.G., Hamburger J.B., and Treuheit M.J. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13 (1996) 996-1002
17. Kinstler O., Molineux G., Treuheit M., Ladd D., and Gegg C. Mono-N-terminal poly(ethylene glycol]-protein conjugates. Adv. Drug Deliv. Rev. 54 (2002) 477-485
18. Fee C.J., and Van Alstine J.M. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug. Chem. 15 (2004) 1304-1313
19. Molineux G. Pegfilgrastim: using PEGylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 14 (2003) 259-264
20. Yowell S.L., and Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat. Rev. 28 Suppl A (2002) 3-6
21. Amgen, Inc., NEULASTA® (pegfilgrastim) Prescribing Information (2006).
22. Curran M.P., and Goa K.L. Pegfilgrastim. Drugs 62 (2002) 1207-1213 (discussion 1214-5)
23. Frampton J.E., and Keating G.M. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia. BioDrugs 19 (2005) 405-407
24. O.B. Kinstler, N.E. Gabriel, C.E. Farrar, R.B. DePrince, N-terminally Chemically Modified Protein Compositions and Methods (1999) US Patent 5985265, Amgen Inc.
25. Ratto J., O'Conner S., Distler A., Wu G., Hummel D., Treuheit M., Herman A., and Davis J. Ethanol-sodium chloride-phosphate mobile phase for size exclusion chromatography of poly(ethylene glycol) modified proteins. J. Chromatgr., A 763 (1996) 337-344
26. Osslund T., and Boone T. Biochemistry and Structure of Filgrastim. 2nd ed. (1998), Marcel Dekker Inc., New York
27. Wong S. Reactive Groups of Proteins and their Modifying Agents (1991), CRC Press, Boston
28. O.B Kinstler, N.E Gabriel, C.E Farrar, R.B DePrince, N-terminally Chemically Modified Protein Compositions and Methods (1998) US Patent 5824784. Amgen Inc.
29. Basu A., Yang K., Wang M., Liu S., Chintala R., Palm T., Zhao H., Peng P., Wu D., Zhang Z., Hua J., Hsieh M.C., Zhou J., Petti G., Li X., Janjua A., Mendez M., Liu J., Longley C., Zhang Z., Mehlig M., Borowski V., Viswanathan M., and Filpula D. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug. Chem. 17 (2006) 618-630
30. Rajan R.S., Li T., Aras M., Sloey C., Sutherland W., Arai H., Briddell R., Kinstler O.B., Lueras A.M., Zhang Y., Yeghnazar H., Treuheit M., and Brems D.N. Modulation of protein aggregation by polyethylene glycol conjugation: G-CSF as a case study. Protein Sci. 15 (2006) 1063-1075
31. Krishnan S., Chi E.Y., Webb J.N., Chang B.S., Shan D., Goldenberg M., Manning M.C., Randolph T.W., and Carpenter J.F. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry 41 (2002) 6422-6431
32. Narhi L.O., Kenney W.C., and Arakawa T. Conformational changes of recombinant human granulocyte-colony stimulating factor induced by pH and guanidine hydrochloride. J. Protein Chem. 10 (1991) 359-367
33. Ricci M.S., Sarkar C.A., Fallon E.M., Lauffenburger D.A., and Brems D.N. pH Dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor. Protein Sci. 12 (2003) 1030-1038
34. Powell M. A Compendium and Hydrophathy/flexibility Analysis of Common Reactive Sites in Proteins: Reactivity at Asn, Asp, Gln, and Met Motifs in Neutral pH solution vol. 9 (1996), Plenum Press, New York
35. Chang B., and Hershenson S. Practical Approaches to Protein Formulation Development vol. 13 (2002), Kluwer Academic/Plenum Publishers, New York
36. Brems D.N. The kinetics of G-CSF folding. Protein Sci. 11 (2002) 2504-2511
37. Costantino H. Excipients for Use in Lyophilized Pharmaceutical Peptide, Protein, and other Bioproducts vol. 2 (2004), American Association of Pharmaceutical Scientists, Arlington, VA
38. Brazeau G.A., Cooper B., Svetic K.A., Smith C.L., and Gupta P. Current perspectives on pain upon injection of drugs. J. Pharm. Sci. 87 (1998) 667-677
39. Chang L.L., Shepherd D., Sun J., Ouellette D., Grant K.L., Tang X.C., and Pikal M.J. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?. J. Pharm. Sci. 94 (2005) 1427-1444
40. Randolph T.W. Phase separation of excipients during lyophilization: effects on protein stability. J. Pharm. Sci. 86 (1997) 1198-1203
41. Piedmonte D.M., Summers C., McAuley A., Karamujic L., and Ratnaswamy G. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm. Res. 24 (2007) 136-146
42. Yin J., Chu J.W., Ricci M.S., Brems D.N., Wang D.I., and Trout B.L. Effects of excipients on the hydrogen peroxide-induced oxidation of methionine residues in granulocyte colony-stimulating factor. Pharm. Res. 22 (2005) 141-147
43. Treuheit M.J., Kosky A.A., and Brems D.N. Inverse relationship of protein concentration and aggregation. Pharm. Res. 19 (2002) 511-516
44. Kreilgaard L., Jones L.S., Randolph T.W., Frokjaer S., Flink J.M., Manning M.C., and Carpenter J.F. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J. Pharm. Sci. 87 (1998) 1597-1603
45. Chang B.S., Kendrick B.S., and Carpenter J.F. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J. Pharm. Sci. 85 (1996) 1325-1330
46. Carpenter J.F., Kendrick B.S., Chang B.S., Manning M.C., and Randolph T.W. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 309 (1999) 236-255
47. Randolph T.W., and Jones L.S. Surfactant-protein Interactions vol. 13 (1996), Plenum Publishers, New York
48. Donbrow M., Azaz E., and Pillersdorf A. Autoxidation of polysorbates. J. Pharm. Sci. 67 (1978) 1676-1681
49. Jaeger J., Sorensen K., and Wolff S.P. Peroxide accumulation in detergents. J. Biochem. Biophys. Methods 29 (1994) 77-81
50. Ha E., Wang W., and Wang Y.J. Peroxide formation in polysorbate 80 and protein stability. J. Pharm. Sci. 91 (2002) 2252-2264
51. European Directorate for the Quality of Medicines, Council of Europe. Polysorbate 80. In: European Pharmacopoeia, 5th ed. Strasbourg, France. 04/2006:0428.
52. O.B. Kinstler, N-terminally Chemically Modified Protein Compositions and Methods (2005) US Patent 6956027B2, Amgen Inc.
53. Hermeling S., Crommelin D.J., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 (2004) 897-903
54. Koren E., Zuckerman L.A., and Mire-Sluis A.R. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3 (2002) 349-360
55. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 Suppl 6 (2005) 3-9